secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001628280-25-023175
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotech Q1 net loss $121M; launches Phase 3 hepatitis delta program; cash into mid-2027
--------------------------------------------------------------------------------

- Net loss of $121.0M ($0.88 per share) vs $65.3M ($0.48) in Q1 2024; revenue $3.0M vs $56.4M.
- Initiated Phase 3 ECLIPSE registrational program for chronic hepatitis delta; first patient enrolled March 2025.
- Cash and investments ~$1.02B, down $75.6M in Q1; cash runway into mid-2027.
- Alnylam opted out of profit-sharing for elebsiran in CHB/CHD; Vir seeking partner for CHB development.
- Dose escalation ongoing for TCEs VIR-5818 (HER2) and VIR-5500 (PSMA); Phase 1 for VIR-5525 (EGFR) planned Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000162828025023175/0001628280-25-023175-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000162828025023175/vir-20250507.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-023175

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer